<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04957823</url>
  </required_header>
  <id_info>
    <org_study_id>Soh-Med-21-06-20</org_study_id>
    <nct_id>NCT04957823</nct_id>
  </id_info>
  <brief_title>Irisin Expression and Gene Polymorphism in Type II Diabetic Patients With and Without CAD</brief_title>
  <acronym>CAD</acronym>
  <official_title>Serum Irisin Level &amp; FDNC5 Genetic Polymorphism Can Predict the Presence &amp;Severity of Coronary Artery Disease in Patients With Type II DM?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observertional study aimed at Study the association between the level of irisin&#xD;
      expression and (Fibronectin Type III Domain Containing 5 (FDNC5) gene polymorphism and the&#xD;
      presence and severity of coronary artery disease in patients with Type II DM.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Irisin level</measure>
    <time_frame>6 months</time_frame>
    <description>detect the serum level of irisin hormone by ELIZA in nanogram/decilitre(ng/dl)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FNDC5 Genotyping</measure>
    <time_frame>6 months</time_frame>
    <description>whether homogenetic or heterogenetic</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Irisin Gene Polymorphism in Type II Diabetic Patients</condition>
  <arm_group>
    <arm_group_label>Diseased</arm_group_label>
    <description>type II diabetic patients with documented coronary artery disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>type II diabetic patients without coronary artery disease.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        type II diabetic patients with and without coronary artery disease in our center in sohag&#xD;
        university hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  This study will include type II diabetic patients aged between 18 and 45 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Recent acute myocardial infarction.&#xD;
&#xD;
          2. patients with Heart Failure&#xD;
&#xD;
          3. Active infection&#xD;
&#xD;
          4. End stage renal failure (GFR &lt; 30 ml/min) or on dialysis&#xD;
&#xD;
          5. Liver cell failure&#xD;
&#xD;
          6. Athletes or having heavy muscular exercise in the previous 3 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Amera Morad Foad hamdy, lecturer</last_name>
    <phone>01006591449</phone>
    <phone_ext>+20</phone_ext>
    <email>ameramoradfoad@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sohag uniersity hosoital</name>
      <address>
        <city>Sohag</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amera morad foad hamdy, lecturer</last_name>
      <phone>01006591449</phone>
      <email>ameramoradfoad@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 3, 2021</study_first_submitted>
  <study_first_submitted_qc>July 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2021</study_first_posted>
  <last_update_submitted>July 3, 2021</last_update_submitted>
  <last_update_submitted_qc>July 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Amera Morad Foad</investigator_full_name>
    <investigator_title>clinical professor</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

